Metastatic Non‐Myofibroblastic Sarcoma Harbouring EML4‐ALK Fusion—Dramatic Response to ALK Tyrosine Kinase Inhibitors and Development of Resistance Mutations

ABSTRACT Background Anaplastic lymphoma kinase (ALK) rearrangements are rare in non‐myofibroblastic sarcoma and there is limited data on the efficacy of ALK tyrosine kinase inhibitors (TKIs) and mechanisms of resistance in these patients. Case A 58 year‐old man with metastatic non‐myofibroblastic sa...

Descripción completa

Detalles Bibliográficos

Autores principales:	Isabella Wilson, Min Qiu, Malinda Itchins, Bin Wang, Min Li Huang, Peter Grimison
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wiley 2024-08-01
Colección:	Cancer Reports
Materias:	alectinib anaplastic lymphoma kinase lorlatinib sarcoma tyrosine kinase inhibitors
Acceso en línea:	https://doi.org/10.1002/cnr2.2164
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!